Table 4.

Annual Change in Plasma Biomarkers and FVC in Antifibrotic Exposed and Nonexposed Individuals

Biomarker	Antifibrotic Nonexposed (n = 23)				Antifibrotic Exposed (n = 33)
	Change	95% CI		P	Change	95% CI		P
CA-125 (pg/mL)	3.78	0.56	6.98	.02	−0.82	−4.92	3.26	.69
CXCL13 (pg/mL)	18.80	1.66	35.96	.03	−10.70	−32.74	11.34	.34
MMP7 (ng/mL)	0.02	−0.14	0.18	.79	−0.04	−0.24	0.16	.68
SP-D (ng/mL)	1.82	0.66	2.96	.002	0.26	−1.20	1.74	.73
YKL-40 (ng/mL)	3.78	−1.26	8.80	.14	−4.68	−11.20	1.72	.15
VCAM-1 (ng/mL)	35.80	2.32	69.40	.04	4.62	−38.18	47.40	.83
Osteopontin (ng/mL)	2.82	1.20	4.42	.001	−0.60	−2.58	1.56	.62
Lung function
FVC, mL	−27.74	−54.20	−1.30	.005	8.80	−25.32	43.10	.33
DLCO, mL/min/mm Hg	−0.31	−0.55	-0.07	.01	0.14	−0.17	0.45	.38

Models adjusted for race, smoking history, and baseline GAP score. See Table 1 legend for expansions of abbreviations.